Alexander G. Markhaev

Alexander G. Markhaev

Auto-generated profile, based on publicly available information

Alexander G. Markhaev

Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Viruses
Verified
Journal Article
Open access
PDF file
NPNatalia V. Palyanova
Natalia V. Palyanova
ISIvan Sobolev
Ivan Sobolev
AAAlexander Yurievich Alekseev
Alexander Yurievich Alekseev
AGAlexandra Glushenko
Alexandra Glushenko
EKEvgeniya Kazachkova
Evgeniya Kazachkova
ASAlexander M. Shestopalov
Alexander M. Shestopalov
In this retrospective, single-center study, we conducted an analysis of 13,699 samples from different individuals obtained from the Federal Research Center of Fundamental and Translational Medicine, from 1 April to 30 May 2020 in Novosibirsk region (population 2.8 million people). We identified 6.49% positive for SARS-CoV-2 cases out of the total number of diagnostic tests, and 42% of them were from asymptomatic people. We also detected two asymptomatic people, who had no confirmed contact with patients with COVID-19. The highest percentage of positive samples was observed in the 80+ group (16.3%), while among the children and adults it did not exceed 8%. Among all the people tested, 2423 came from a total of 80 different destinations and only 27 of them were positive for SARS-CoV-2. Out of all the positive samples, 15 were taken for SARS-CoV-2 sequencing. According to the analysis of the genome sequences, the SARS-CoV-2 variants isolated in the Novosibirsk region at the beginning of the pandemic belonged to three phylogenetic lineages according to the Pangolin classification: B.1, B.1.1, and B.1.1.129. All Novosibirsk isolates contained the D614G substitution in the Spike protein, two isolates werecharacterized by an additional M153T mutation, and one isolate wascharacterized by the L5F mutation.

26 January 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
PSPavel Solodkov
Pavel Solodkov
ANAlexander M. Najakshin
Alexander M. Najakshin
NCNikolai A. Chikaev
Nikolai A. Chikaev
SKSergey V Kulemzin
Sergey V Kulemzin
LMLudmila V. Mechetina
Ludmila V. Mechetina
ATAlexander V Taranin
Alexander V Taranin
The emergence of SARS-CoV-2 mutant variants has posed a significant challenge to both the prevention and treatment of COVID-19 with anti-coronaviral neutralizing antibodies. The latest viral variants demonstrate pronounced resistance to the vast majority of human monoclonal antibodies raised against the ancestral Wuhan variant. Less is known about the susceptibility of the evolved virus to camelid nanobodies developed at the start of the pandemic. In this study, we compared nanobody repertoires raised in the same llama after immunization with Wuhan’s RBD variant and after subsequent serial immunization with a variety of RBD variants, including that of SARS-CoV-1. We show that initial immunization induced highly potent nanobodies, which efficiently protected Syrian hamsters from infection with the ancestral Wuhan virus. These nanobodies, however, mostly lacked the activity against SARS-CoV-2 omicron-pseudotyped viruses. In contrast, serial immunization with different RBD variants resulted in the generation of nanobodies demonstrating a higher degree of somatic mutagenesis and a broad range of neutralization. Four nanobodies recognizing distinct epitopes were shown to potently neutralize a spectrum of omicron variants, including those of the XBB sublineage. Our data show that nanobodies broadly neutralizing SARS-CoV-2 variants may be readily induced by a serial variant RBD immunization.